The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Inclusion Criteria:

• Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2)
• Have an increased waist to height ratio (defined by >0.5)
• Have at least one weight related comorbid condition
• Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)

Exclusion Criteria:

• Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
• Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.